CLINICAL ADVANCES
Targeting BTK in Hematologic Malignancies
Read Overview
Supported by an independent educational grant from Astrazeneca Pharmaceuticals LP
Overview
CME Activities
Resources
- Ibrutinib Regimens Versus Chemoimmunotherapy in Older Patients With Untreated CLL
- Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- Acalabrutinib With or Without Obinutuzumab Versus Chlorambucil and Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukemia (ELEVATE TN): A Randomised, Controlled, Phase 3 Trial
- Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Steering Committee
Jennifer A. Woyach, MD
Steering Committee Chair
Professor of Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Jennifer R. Brown, MD, PhD
Steering Committee Member
Professor of Medicine
Harvard Medical School
Director, Center for Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
Boston, Massachusetts
Matthew S. Davids, MD, MMSc
Steering Committee Member
Associate Professor of Medicine
Harvard Medical School
Director, Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Anthony Mato, MD, MSCE
Steering Committee Member
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, New York
John Pagel, MD, PhD
Steering Committee Member
Chief of Hematologic Malignancies
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute
Seattle, Washington
Deborah Stephens, DO
Steering Committee Member
Assistant Professor of Medicine
Division of Hematology
University of Utah
Huntsman Cancer Institute
Salt Lake City, Utah
Disclosures
Steering Committee
Jennifer A. Woyach, MD
Steering Committee Chair
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; ArQule; AstraZeneca; Janssen; Pharmacyclics
Received grants for clinical research from: AbbVie; Janssen; Karyopharm; Loxo; MorphoSys; Pharmacyclics; Verastem
Jennifer R. Brown, MD, PhD
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbvie; Acerta; AstraZeneca; BeiGene; Catapult; Eli Lilly; MEI Pharma; Novartis; Octapharma; Pfizer; Rigel
Served as a speaker or a member of a speakers bureau for: Gilead; Loxo; Sun; Verastem
Other: DSMB: Invectys
Matthew S. Davids, MD, MMSc
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene; Celgene; Eli Lilly; Genentech; Janssen; Merck; Novartis; Pharmacyclics; TG Therapeutics; Verastem; Zentalis
Served as a speaker or a member of a speakers bureau for: Research to Practice
Received grants for clinical research from: AstraZeneca; Genentech; MEI Pharma; Novartis; Pharmacyclics; Surface Oncology; TG Therapeutics; Verastem
Anthony Mato, MD, MSCE
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; AstraZeneca; Johnson & Johnson Pharmaceutical Research & Development, LLC; Pharmacyclics; TS Therapeutics
Received grants for clinical research from: AbbVie; Johnson & Johnson Pharmaceutical Research & Development, LLC; Loxo Oncology; Pharmacyclics; Regeneron Pharmaceuticals, Inc.; Sunesis Pharmaceuticals, Inc.; TS Therapeutics
John Pagel, MD, PhD
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca; BeiGene; Gilead; MorphoSys; Seagen
Deborah Stephens, DO
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Adaptive Biotechnologies; Innate; Janssen/Pharmacyclics; Karyopharm; TG Therapeutics
Received grants for clinical research from: Acerta; ArQule; Juno; Karyopharm; MingSight
Discussion